Cargando…
Covalent inhibitor targets KRas(G12C): A new paradigm for drugging the undruggable and challenges ahead
KRAS is one of the most commonly mutated oncogenes in cancers and therapeutics directly targeting the KRas have been challenging. Among the different known mutants, KRas(G12C) has been proved to be successfully targeted recently. Several covalent inhibitors selectively targeting KRas(G12C) have show...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Chongqing Medical University
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201555/ https://www.ncbi.nlm.nih.gov/pubmed/37223497 http://dx.doi.org/10.1016/j.gendis.2021.08.011 |